Soligenix “announced the pricing of its public offering of 11,875,000 shares of common stock and warrants to purchase up to 11,875,000 shares of common stock at a combined public offering price of $0.40 per share and accompanying warrant for aggregate gross proceeds of approximately $4.75 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $0.40 per share, will be exercisable immediately and will expire five years from the issuance date. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNGX:
- Soligenix: FDA grants orphan drug designation for active ingredient in MarVax
- Soligenix confirms FDA orphan designation for active ingredient in SuVax
- Soligenix prophylaxis against Sudan Ebola Virus gets FDA orphan designation
- Soligenix prevention against Marburg marburgvirus gets FDA orphan designation
- Soligenix reaches agreement with EMA on second HyBryte trial